On appeal, Pfizer and Merck KGaA convince England’s NICE to back Bavencio in bladder cancernews2022-04-07T15:30:47+00:00April 7th, 2022|Fierce Pharma|
Pfizer rolls out voluntary retirement scheme in India as it dives deeper into digitalnews2022-04-07T15:05:07+00:00April 7th, 2022|Fierce Pharma|
Alnylam founder Maraganore snags $10.2M pay in his farewell year, as new CEO Greenstreet grabs $8.6Mnews2022-04-07T13:57:51+00:00April 7th, 2022|Fierce Pharma|
Superior Patient Engagement – A “Must Have” For Biopharmanews2022-04-07T13:51:27+00:00April 7th, 2022|Fierce Pharma|
A seasonal COVID-19 booster shot? Don’t count on it in the U.S. or Europenews2022-04-07T13:28:09+00:00April 7th, 2022|Fierce Pharma|
Asymchem completes construction at new Chinese production sitesnews2022-04-07T13:12:10+00:00April 7th, 2022|Fierce Pharma|
Akebia reveals sweeping layoffs and vadadustat partial clinical hold after FDA snubnews2022-04-07T13:00:17+00:00April 7th, 2022|Fierce Pharma|
Catalent buys partially built biologics plant with plans to shell out $160M to finish itnews2022-04-07T12:30:10+00:00April 7th, 2022|Fierce Pharma|
With €7B pledge, Boehringer Ingelheim is going heavy on investment—including in manufacturingnews2022-04-06T19:50:13+00:00April 6th, 2022|Fierce Pharma|
AAN: AstraZeneca touts new Ultomiris gMG data ahead of potential Argenx showdownnews2022-04-06T15:11:33+00:00April 6th, 2022|Fierce Pharma|
